| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 96 | 2020 | 27125 | 2.430 |
Why?
|
| Neoplasms | 43 | 2020 | 17034 | 1.990 |
Why?
|
| Genome, Human | 39 | 2020 | 4327 | 1.980 |
Why?
|
| Genes, Neoplasm | 8 | 2018 | 383 | 1.800 |
Why?
|
| DNA Mutational Analysis | 23 | 2019 | 4345 | 1.690 |
Why?
|
| High-Throughput Nucleotide Sequencing | 22 | 2019 | 3003 | 1.690 |
Why?
|
| Genomics | 32 | 2019 | 4291 | 1.560 |
Why?
|
| Sequence Analysis, DNA | 27 | 2019 | 5047 | 1.500 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 14 | 2019 | 1056 | 1.280 |
Why?
|
| DNA Damage | 7 | 2019 | 2432 | 1.070 |
Why?
|
| Sequence Analysis, RNA | 8 | 2019 | 1712 | 1.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 33 | 2020 | 8263 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 25 | 2019 | 4837 | 1.010 |
Why?
|
| Microsatellite Repeats | 4 | 2019 | 833 | 0.980 |
Why?
|
| DNA Copy Number Variations | 24 | 2020 | 1561 | 0.960 |
Why?
|
| INDEL Mutation | 3 | 2020 | 227 | 0.930 |
Why?
|
| Gene Dosage | 14 | 2020 | 1278 | 0.920 |
Why?
|
| Mutagenesis | 5 | 2019 | 1298 | 0.900 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2020 | 65 | 0.890 |
Why?
|
| DNA Polymerase II | 2 | 2018 | 121 | 0.800 |
Why?
|
| Artifacts | 3 | 2018 | 1820 | 0.790 |
Why?
|
| DNA Polymerase III | 1 | 2018 | 55 | 0.770 |
Why?
|
| Oncogenes | 8 | 2018 | 1092 | 0.760 |
Why?
|
| DNA, Neoplasm | 7 | 2019 | 1866 | 0.740 |
Why?
|
| Databases, Genetic | 10 | 2020 | 1656 | 0.740 |
Why?
|
| Point Mutation | 8 | 2017 | 1718 | 0.730 |
Why?
|
| Oncogene Proteins | 4 | 2020 | 764 | 0.710 |
Why?
|
| Genetic Heterogeneity | 7 | 2019 | 715 | 0.690 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2020 | 1831 | 0.660 |
Why?
|
| Software | 9 | 2019 | 4194 | 0.640 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 317 | 0.630 |
Why?
|
| Lung Neoplasms | 17 | 2020 | 10674 | 0.580 |
Why?
|
| Germ-Line Mutation | 8 | 2019 | 1476 | 0.570 |
Why?
|
| Models, Genetic | 6 | 2019 | 3605 | 0.540 |
Why?
|
| DNA Repair | 6 | 2018 | 1961 | 0.540 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 1047 | 0.530 |
Why?
|
| Chromosome Aberrations | 10 | 2018 | 1740 | 0.520 |
Why?
|
| Adenocarcinoma | 15 | 2016 | 6294 | 0.510 |
Why?
|
| Protein Kinase Inhibitors | 17 | 2019 | 4969 | 0.510 |
Why?
|
| Melanoma | 12 | 2018 | 5133 | 0.510 |
Why?
|
| Evolution, Molecular | 7 | 2019 | 1924 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 15 | 2020 | 2875 | 0.500 |
Why?
|
| Gene Amplification | 9 | 2016 | 1080 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2019 | 170 | 0.490 |
Why?
|
| Humans | 175 | 2020 | 627531 | 0.490 |
Why?
|
| Mutation, Missense | 5 | 2016 | 2421 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 3711 | 0.480 |
Why?
|
| Cell Line, Tumor | 35 | 2019 | 16509 | 0.470 |
Why?
|
| Gene Expression Profiling | 21 | 2019 | 9431 | 0.450 |
Why?
|
| Proto-Oncogene Proteins B-raf | 9 | 2019 | 1734 | 0.450 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 1122 | 0.440 |
Why?
|
| Endometrial Neoplasms | 4 | 2018 | 1234 | 0.410 |
Why?
|
| Genetic Techniques | 1 | 2012 | 454 | 0.410 |
Why?
|
| Breast Neoplasms | 9 | 2018 | 18451 | 0.400 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2018 | 2871 | 0.400 |
Why?
|
| Antigens, Neoplasm | 6 | 2018 | 2055 | 0.370 |
Why?
|
| Consensus Sequence | 1 | 2007 | 410 | 0.360 |
Why?
|
| Genomic Instability | 5 | 2019 | 639 | 0.350 |
Why?
|
| Computational Biology | 8 | 2017 | 3309 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2019 | 16103 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 6291 | 0.340 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2019 | 1113 | 0.320 |
Why?
|
| Genetic Variation | 7 | 2018 | 6351 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2018 | 801 | 0.310 |
Why?
|
| Genome-Wide Association Study | 15 | 2020 | 9972 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2016 | 564 | 0.310 |
Why?
|
| Neoplasm Proteins | 6 | 2017 | 3748 | 0.310 |
Why?
|
| Clone Cells | 5 | 2019 | 1755 | 0.300 |
Why?
|
| Lactams, Macrocyclic | 2 | 2016 | 266 | 0.300 |
Why?
|
| Microsatellite Instability | 2 | 2019 | 638 | 0.300 |
Why?
|
| Antineoplastic Agents | 15 | 2019 | 13348 | 0.300 |
Why?
|
| DNA | 4 | 2019 | 7406 | 0.300 |
Why?
|
| DNA Replication | 3 | 2018 | 1478 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2016 | 4055 | 0.280 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 5168 | 0.280 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2016 | 191 | 0.280 |
Why?
|
| Cholangiocarcinoma | 2 | 2019 | 449 | 0.280 |
Why?
|
| Disease Progression | 12 | 2019 | 12439 | 0.270 |
Why?
|
| Gene Regulatory Networks | 5 | 2018 | 1550 | 0.270 |
Why?
|
| Quality Control | 2 | 2019 | 851 | 0.270 |
Why?
|
| Multiple Myeloma | 5 | 2020 | 4339 | 0.270 |
Why?
|
| Sample Size | 3 | 2016 | 713 | 0.260 |
Why?
|
| Craniopharyngioma | 2 | 2015 | 231 | 0.260 |
Why?
|
| DNA Methylation | 6 | 2020 | 3783 | 0.260 |
Why?
|
| Brain Neoplasms | 7 | 2019 | 8048 | 0.260 |
Why?
|
| Liposarcoma | 2 | 2019 | 304 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2015 | 2628 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 7 | 2019 | 2643 | 0.260 |
Why?
|
| Cancer Vaccines | 3 | 2018 | 958 | 0.260 |
Why?
|
| Colorectal Neoplasms | 5 | 2015 | 5672 | 0.260 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2013 | 104 | 0.250 |
Why?
|
| Alleles | 7 | 2018 | 6925 | 0.250 |
Why?
|
| Cell Proliferation | 13 | 2019 | 10916 | 0.240 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2016 | 787 | 0.240 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2018 | 543 | 0.240 |
Why?
|
| Translocation, Genetic | 4 | 2016 | 1423 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2019 | 3096 | 0.240 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2017 | 650 | 0.230 |
Why?
|
| Glioma | 4 | 2018 | 2893 | 0.230 |
Why?
|
| Phosphoproteins | 4 | 2020 | 2690 | 0.230 |
Why?
|
| Osteosarcoma | 2 | 2018 | 898 | 0.230 |
Why?
|
| Carcinoma | 3 | 2019 | 2337 | 0.230 |
Why?
|
| Cluster Analysis | 7 | 2018 | 2717 | 0.230 |
Why?
|
| Prenylation | 1 | 2019 | 40 | 0.220 |
Why?
|
| Cohort Studies | 14 | 2019 | 35693 | 0.220 |
Why?
|
| Reed-Sternberg Cells | 1 | 2019 | 87 | 0.220 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 1187 | 0.210 |
Why?
|
| Genes, p53 | 2 | 2012 | 794 | 0.210 |
Why?
|
| Bayes Theorem | 4 | 2018 | 1539 | 0.210 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 1368 | 0.210 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 2436 | 0.210 |
Why?
|
| E2F Transcription Factors | 2 | 2017 | 291 | 0.210 |
Why?
|
| False Positive Reactions | 2 | 2013 | 1030 | 0.210 |
Why?
|
| Apyrase | 2 | 2019 | 373 | 0.210 |
Why?
|
| Chromosome Deletion | 5 | 2016 | 1346 | 0.210 |
Why?
|
| Kynurenine | 1 | 2019 | 93 | 0.200 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2019 | 213 | 0.200 |
Why?
|
| Contact Inhibition | 1 | 2018 | 56 | 0.200 |
Why?
|
| Genetic Loci | 3 | 2018 | 2490 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 10051 | 0.200 |
Why?
|
| Mediastinal Neoplasms | 2 | 2019 | 447 | 0.200 |
Why?
|
| Female | 54 | 2020 | 352544 | 0.200 |
Why?
|
| Gene Deletion | 3 | 2019 | 2909 | 0.200 |
Why?
|
| Genomic Structural Variation | 1 | 2018 | 52 | 0.190 |
Why?
|
| Glioblastoma | 4 | 2019 | 3060 | 0.190 |
Why?
|
| Ploidies | 3 | 2013 | 276 | 0.190 |
Why?
|
| Cyclin E | 2 | 2020 | 161 | 0.190 |
Why?
|
| Multigene Family | 3 | 2018 | 1194 | 0.190 |
Why?
|
| Protein Structure, Tertiary | 7 | 2015 | 4406 | 0.190 |
Why?
|
| Poisson Distribution | 1 | 2019 | 519 | 0.190 |
Why?
|
| Computer Graphics | 1 | 2019 | 354 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1578 | 0.190 |
Why?
|
| Ovarian Neoplasms | 5 | 2014 | 4526 | 0.190 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2019 | 243 | 0.190 |
Why?
|
| Dog Diseases | 1 | 2018 | 149 | 0.180 |
Why?
|
| Allelic Imbalance | 1 | 2017 | 74 | 0.180 |
Why?
|
| Pituitary Neoplasms | 2 | 2015 | 1162 | 0.180 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2017 | 156 | 0.180 |
Why?
|
| Gene Rearrangement | 7 | 2018 | 1120 | 0.180 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 543 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 1520 | 0.180 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 1391 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2016 | 124 | 0.180 |
Why?
|
| CA-125 Antigen | 1 | 2019 | 276 | 0.180 |
Why?
|
| Signal Transduction | 19 | 2019 | 23809 | 0.170 |
Why?
|
| Dogs | 3 | 2018 | 4361 | 0.170 |
Why?
|
| Single-Cell Analysis | 4 | 2018 | 1367 | 0.170 |
Why?
|
| DNA-Binding Proteins | 9 | 2020 | 9938 | 0.170 |
Why?
|
| Male | 50 | 2020 | 333300 | 0.170 |
Why?
|
| Alternative Splicing | 3 | 2019 | 1161 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2018 | 584 | 0.170 |
Why?
|
| Immune Evasion | 2 | 2019 | 223 | 0.170 |
Why?
|
| Organ Specificity | 2 | 2019 | 2047 | 0.170 |
Why?
|
| MicroRNAs | 6 | 2019 | 3541 | 0.170 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2015 | 449 | 0.170 |
Why?
|
| Genes, X-Linked | 1 | 2016 | 125 | 0.170 |
Why?
|
| Quinazolines | 3 | 2016 | 1492 | 0.170 |
Why?
|
| Endometrial Hyperplasia | 1 | 2016 | 71 | 0.170 |
Why?
|
| Algorithms | 10 | 2018 | 12814 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 7602 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2019 | 1374 | 0.170 |
Why?
|
| Tobacco | 2 | 2016 | 333 | 0.170 |
Why?
|
| B-Lymphocytes | 4 | 2019 | 4697 | 0.160 |
Why?
|
| Pyrimidines | 6 | 2019 | 2733 | 0.160 |
Why?
|
| Catalytic Domain | 2 | 2015 | 767 | 0.160 |
Why?
|
| beta Catenin | 4 | 2014 | 1090 | 0.160 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2019 | 515 | 0.160 |
Why?
|
| RNA Splicing | 3 | 2019 | 877 | 0.160 |
Why?
|
| Sulfonamides | 4 | 2019 | 1751 | 0.160 |
Why?
|
| Leiomyosarcoma | 1 | 2019 | 426 | 0.160 |
Why?
|
| Genes, p16 | 2 | 2012 | 157 | 0.160 |
Why?
|
| Models, Molecular | 7 | 2016 | 5857 | 0.160 |
Why?
|
| Esophageal Neoplasms | 2 | 2015 | 1342 | 0.160 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 82 | 0.160 |
Why?
|
| Oligodendroglioma | 1 | 2016 | 277 | 0.160 |
Why?
|
| Protein Binding | 4 | 2017 | 10041 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 430 | 0.160 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 308 | 0.160 |
Why?
|
| Base Sequence | 9 | 2014 | 14149 | 0.150 |
Why?
|
| Chromatin | 4 | 2014 | 2376 | 0.150 |
Why?
|
| Angiomyolipoma | 1 | 2016 | 187 | 0.150 |
Why?
|
| Pulmonary Blastoma | 1 | 2014 | 31 | 0.150 |
Why?
|
| Pelvic Neoplasms | 1 | 2016 | 231 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 459 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 2043 | 0.150 |
Why?
|
| Uveal Neoplasms | 1 | 2017 | 304 | 0.150 |
Why?
|
| Thyroid Neoplasms | 2 | 2018 | 1892 | 0.150 |
Why?
|
| Exons | 5 | 2012 | 2506 | 0.150 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 236 | 0.150 |
Why?
|
| Loss of Heterozygosity | 5 | 2017 | 700 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2016 | 301 | 0.150 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2014 | 341 | 0.150 |
Why?
|
| Selection, Genetic | 1 | 2019 | 886 | 0.150 |
Why?
|
| Oligodendroglia | 1 | 2018 | 507 | 0.150 |
Why?
|
| Retinoblastoma Protein | 2 | 2015 | 730 | 0.140 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 18412 | 0.140 |
Why?
|
| Cytidine Deaminase | 1 | 2015 | 233 | 0.140 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 8250 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 205 | 0.140 |
Why?
|
| DNA Replication Timing | 1 | 2013 | 43 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 183 | 0.140 |
Why?
|
| Antigen Presentation | 2 | 2017 | 1334 | 0.140 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2016 | 216 | 0.140 |
Why?
|
| Testicular Neoplasms | 2 | 2016 | 715 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 1564 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 706 | 0.140 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 1743 | 0.140 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 597 | 0.140 |
Why?
|
| Retroelements | 1 | 2014 | 143 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 181 | 0.140 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2018 | 348 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 269 | 0.140 |
Why?
|
| Polyploidy | 1 | 2013 | 124 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2014 | 4365 | 0.140 |
Why?
|
| Databases, Protein | 1 | 2015 | 394 | 0.140 |
Why?
|
| Phenotype | 10 | 2020 | 14970 | 0.130 |
Why?
|
| Ribonuclease III | 1 | 2014 | 247 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2019 | 1854 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 331 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 406 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 814 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 790 | 0.130 |
Why?
|
| Encyclopedias as Topic | 1 | 2012 | 22 | 0.130 |
Why?
|
| Aneuploidy | 2 | 2012 | 409 | 0.130 |
Why?
|
| Genomic Library | 1 | 2012 | 215 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 755 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2018 | 734 | 0.130 |
Why?
|
| Sirtuins | 1 | 2015 | 353 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 733 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 516 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2018 | 14873 | 0.130 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 9873 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 4487 | 0.130 |
Why?
|
| Gene Library | 2 | 2012 | 1111 | 0.130 |
Why?
|
| Apoptosis | 8 | 2019 | 10323 | 0.130 |
Why?
|
| Qb-SNARE Proteins | 1 | 2011 | 39 | 0.130 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 942 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 4107 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 1839 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2017 | 13810 | 0.120 |
Why?
|
| Cisplatin | 2 | 2017 | 1665 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2018 | 5994 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 2198 | 0.120 |
Why?
|
| Pyrazoles | 3 | 2019 | 1636 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 2 | 2013 | 498 | 0.120 |
Why?
|
| Urothelium | 1 | 2014 | 322 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 926 | 0.120 |
Why?
|
| Protein Biosynthesis | 2 | 2017 | 2223 | 0.120 |
Why?
|
| Gene Fusion | 4 | 2016 | 254 | 0.120 |
Why?
|
| ROC Curve | 1 | 2019 | 3372 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2015 | 295 | 0.120 |
Why?
|
| Guanine | 1 | 2013 | 287 | 0.120 |
Why?
|
| Rhabdomyosarcoma | 1 | 2014 | 364 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2012 | 164 | 0.120 |
Why?
|
| Barrett Esophagus | 1 | 2015 | 482 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2017 | 1137 | 0.120 |
Why?
|
| Genome, Fungal | 1 | 2012 | 218 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1336 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2011 | 160 | 0.120 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 316 | 0.120 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 3244 | 0.120 |
Why?
|
| Spliceosomes | 1 | 2011 | 153 | 0.120 |
Why?
|
| RNA, Ribosomal | 1 | 2012 | 254 | 0.120 |
Why?
|
| Neurofibromin 1 | 1 | 2012 | 180 | 0.120 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 680 | 0.120 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 406 | 0.120 |
Why?
|
| Middle Aged | 29 | 2020 | 204499 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 358 | 0.120 |
Why?
|
| Adult | 28 | 2020 | 199203 | 0.120 |
Why?
|
| Cell Survival | 8 | 2016 | 6433 | 0.110 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2010 | 55 | 0.110 |
Why?
|
| Skin Neoplasms | 3 | 2013 | 4907 | 0.110 |
Why?
|
| Hematopoiesis | 1 | 2020 | 1908 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2019 | 4320 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 2326 | 0.110 |
Why?
|
| Schizosaccharomyces | 1 | 2012 | 242 | 0.110 |
Why?
|
| Sunlight | 1 | 2012 | 317 | 0.110 |
Why?
|
| Ultraviolet Rays | 2 | 2012 | 1047 | 0.110 |
Why?
|